GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (NAS:CODX) » Definitions » Beneish M-Score

Co-Diagnostics (Co-Diagnostics) Beneish M-Score : -5.02 (As of Apr. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Co-Diagnostics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -5.02 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Co-Diagnostics's Beneish M-Score or its related term are showing as below:

CODX' s Beneish M-Score Range Over the Past 10 Years
Min: -5.02   Med: 0.41   Max: 306.1
Current: -5.02

During the past 9 years, the highest Beneish M-Score of Co-Diagnostics was 306.10. The lowest was -5.02. And the median was 0.41.


Co-Diagnostics Beneish M-Score Historical Data

The historical data trend for Co-Diagnostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics Beneish M-Score Chart

Co-Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only 1.92 306.10 0.41 -3.95 -5.02

Co-Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.95 -4.03 -4.47 -4.01 -5.02

Competitive Comparison of Co-Diagnostics's Beneish M-Score

For the Medical Devices subindustry, Co-Diagnostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Beneish M-Score falls into.



Co-Diagnostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Co-Diagnostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.308+0.528 * 2.1779+0.404 * 1.2789+0.892 * 0.1991+0.115 * 1.7975
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 4.9145+4.679 * -0.17503-0.327 * 2.5997
=-5.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.33 Mil.
Revenue was 3.555 + 2.457 + 0.198 + 0.602 = $6.81 Mil.
Gross Profit was 0.587 + 2.201 + -0.261 + 0.1 = $2.63 Mil.
Total Current Assets was $62.14 Mil.
Total Assets was $95.32 Mil.
Property, Plant and Equipment(Net PPE) was $6.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.23 Mil.
Selling, General, & Admin. Expense(SGA) was $21.14 Mil.
Total Current Liabilities was $5.75 Mil.
Long-Term Debt & Capital Lease Obligation was $2.15 Mil.
Net Income was -14.676 + -5.982 + -8.919 + -5.755 = $-35.33 Mil.
Non Operating Income was 0.538 + 0.517 + 0.645 + 1.733 = $3.43 Mil.
Cash Flow from Operations was -4.779 + -6.594 + -5.209 + -5.499 = $-22.08 Mil.
Total Receivables was $5.40 Mil.
Revenue was 1.401 + 5.094 + 5.023 + 22.699 = $34.22 Mil.
Gross Profit was 0.886 + 4.327 + 4.108 + 19.417 = $28.74 Mil.
Total Current Assets was $92.73 Mil.
Total Assets was $123.09 Mil.
Property, Plant and Equipment(Net PPE) was $2.91 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.28 Mil.
Selling, General, & Admin. Expense(SGA) was $21.61 Mil.
Total Current Liabilities was $3.87 Mil.
Long-Term Debt & Capital Lease Obligation was $0.05 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.331 / 6.812) / (5.399 / 34.217)
=0.048591 / 0.157787
=0.308

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(28.738 / 34.217) / (2.627 / 6.812)
=0.839875 / 0.385643
=2.1779

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (62.141 + 6.003) / 95.321) / (1 - (92.734 + 2.912) / 123.086)
=0.28511 / 0.222934
=1.2789

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=6.812 / 34.217
=0.1991

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.282 / (1.282 + 2.912)) / (1.23 / (1.23 + 6.003))
=0.305675 / 0.170054
=1.7975

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(21.14 / 6.812) / (21.607 / 34.217)
=3.103347 / 0.63147
=4.9145

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.152 + 5.748) / 95.321) / ((0.051 + 3.873) / 123.086)
=0.082878 / 0.03188
=2.5997

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-35.332 - 3.433 - -22.081) / 95.321
=-0.17503

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Co-Diagnostics has a M-score of -5.02 suggests that the company is unlikely to be a manipulator.


Co-Diagnostics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Co-Diagnostics (Co-Diagnostics) Business Description

Traded in Other Exchanges
Address
2401 South Foothill Drive, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.
Executives
Brian Lee Brown officer: Chief Financial Officer 5322 W. BRIAR PARK ROAD, HERRIMAN UT 84096
Ted Murphy director 64 INDUSTRIAL RD., RICHMOND HILL A6 L4C2Y1
Eugene Durenard director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Dwight H Egan director, officer: CEO and President 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Richard S Serbin director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
James B Nelson director 26 WEST MISSION AVENUE, SUITE 8, SANTA BARBARA CA 93010
Reed L Benson officer: CFO and Secretary 7050 UNION PARK CENTER, #600, SALT LAKE CITY UT 84047
Edward L. Murphy director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Brent Satterfield director, officer: Chief Science Officer 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
America 2030 Capital, Llc 10 percent owner 1301 SHILOH RD., NW, SUITE 1231, KENNESAW GA 30144
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Frank J Kiesner director 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Reagents, Llc 10 percent owner 8160 S. HIGHLAND DR, SANDY UT 84093
Legends Capital Group, Llc 10 percent owner 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124